Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPILOG
NCT00269880Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 1995
- Primary completion
- Dec 1995
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of abciximab in coronary artery disease (CAD), sponsored by Janssen Pharmaceutical. Started Feb 1995; status: completed.
02
Drugs
abciximab
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00269880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269880.